Limits...
Association Study of Fat-mass and Obesity-associated Gene and Body Mass Index in Japanese Patients with Schizophrenia and Healthy Subjects.

Watanabe SY, Iga J, Numata S, Nakataki M, Tanahashi T, Itakura M, Ohmori T - Clin Psychopharmacol Neurosci (2012)

Bottom Line: No significant difference in BMI was observed among any medications.We observed no significant difference in rs9939609 allele frequencies between patients and healthy subjects.We also observed a significant positive correlation between the number of risk allele (A allele) and BMI in healthy subjects.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Course of Integrated Brain Sciences, University of Tokushima School of Medicine, Tokushima, Japan.

ABSTRACT

Objective: Fat-mass and obesity-associated (FTO) gene is known to be involved in the pathophysiology of obesity and a single-nucleotide polymorphism (SNP) rs9939609 of FTO gene is repeatedly confirmed to be associated with body mass index (BMI) and obesity. The aim of this study is to elucidate effects of FTO gene polymorphism on BMI in Japanese patients with schizophrenia and healthy subjects.

Methods: Three hundred fifty one patients with schizophrenia and 342 age- and sex-matched healthy subjects participated in the study. Information on BMI and antipsychotic medication was also collected from patients and healthy subjects. Genotype of the FTO SNP rs9939609 was determined by TaqMan SNP Genotyping Assays.

Results: There was no significant difference in BMI between patients and healthy subjects. No significant difference in BMI was observed among any medications. We observed no significant difference in rs9939609 allele frequencies between patients and healthy subjects. There was a significant difference in BMI between healthy subjects with risk (AA or TA) genotypes and those with TT genotype. We also observed a significant positive correlation between the number of risk allele (A allele) and BMI in healthy subjects.

Conclusion: Our study suggested that FTO rs9939609 polymorphism might have some impacts on the BMI in healthy subjects, but might not have same impacts on the BMI of patients with schizophrenia.

No MeSH data available.


Related in: MedlinePlus

Most patients (62.4%) were treated with poly-pharmacy. No significant difference in body mass index (BMI) was observed among any medications. Poly, polypharmacy; RIS, risperidone; OLZ, olanzapine; PER, perospirone; QUE, quetiapine; HPD, haloperidol.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3569167&req=5

Figure 1: Most patients (62.4%) were treated with poly-pharmacy. No significant difference in body mass index (BMI) was observed among any medications. Poly, polypharmacy; RIS, risperidone; OLZ, olanzapine; PER, perospirone; QUE, quetiapine; HPD, haloperidol.

Mentions: We included 351 schizophrenia patients (224 men and 127 women; mean age 52.32 years, standard deviation [SD] 13.74 years; mean BMI 23.86 kg/m2, SD 4.01 kg/m2), and 343 healthy subjects (228 men and 115 women; mean age 50.68 years, SD 11.62 years; mean BMI 23.38 kg/m2, SD 2.75 kg/m2). The characteristics of patients and healthy subjects are shown in Table 1. There was no significant difference in BMI between patients and healthy subjects. Information about medication in 346 patients was available. Most patients (62.4%) were treated with poly-pharmacy. No significant difference in BMI was observed among any medications (Fig. 1).


Association Study of Fat-mass and Obesity-associated Gene and Body Mass Index in Japanese Patients with Schizophrenia and Healthy Subjects.

Watanabe SY, Iga J, Numata S, Nakataki M, Tanahashi T, Itakura M, Ohmori T - Clin Psychopharmacol Neurosci (2012)

Most patients (62.4%) were treated with poly-pharmacy. No significant difference in body mass index (BMI) was observed among any medications. Poly, polypharmacy; RIS, risperidone; OLZ, olanzapine; PER, perospirone; QUE, quetiapine; HPD, haloperidol.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3569167&req=5

Figure 1: Most patients (62.4%) were treated with poly-pharmacy. No significant difference in body mass index (BMI) was observed among any medications. Poly, polypharmacy; RIS, risperidone; OLZ, olanzapine; PER, perospirone; QUE, quetiapine; HPD, haloperidol.
Mentions: We included 351 schizophrenia patients (224 men and 127 women; mean age 52.32 years, standard deviation [SD] 13.74 years; mean BMI 23.86 kg/m2, SD 4.01 kg/m2), and 343 healthy subjects (228 men and 115 women; mean age 50.68 years, SD 11.62 years; mean BMI 23.38 kg/m2, SD 2.75 kg/m2). The characteristics of patients and healthy subjects are shown in Table 1. There was no significant difference in BMI between patients and healthy subjects. Information about medication in 346 patients was available. Most patients (62.4%) were treated with poly-pharmacy. No significant difference in BMI was observed among any medications (Fig. 1).

Bottom Line: No significant difference in BMI was observed among any medications.We observed no significant difference in rs9939609 allele frequencies between patients and healthy subjects.We also observed a significant positive correlation between the number of risk allele (A allele) and BMI in healthy subjects.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Course of Integrated Brain Sciences, University of Tokushima School of Medicine, Tokushima, Japan.

ABSTRACT

Objective: Fat-mass and obesity-associated (FTO) gene is known to be involved in the pathophysiology of obesity and a single-nucleotide polymorphism (SNP) rs9939609 of FTO gene is repeatedly confirmed to be associated with body mass index (BMI) and obesity. The aim of this study is to elucidate effects of FTO gene polymorphism on BMI in Japanese patients with schizophrenia and healthy subjects.

Methods: Three hundred fifty one patients with schizophrenia and 342 age- and sex-matched healthy subjects participated in the study. Information on BMI and antipsychotic medication was also collected from patients and healthy subjects. Genotype of the FTO SNP rs9939609 was determined by TaqMan SNP Genotyping Assays.

Results: There was no significant difference in BMI between patients and healthy subjects. No significant difference in BMI was observed among any medications. We observed no significant difference in rs9939609 allele frequencies between patients and healthy subjects. There was a significant difference in BMI between healthy subjects with risk (AA or TA) genotypes and those with TT genotype. We also observed a significant positive correlation between the number of risk allele (A allele) and BMI in healthy subjects.

Conclusion: Our study suggested that FTO rs9939609 polymorphism might have some impacts on the BMI in healthy subjects, but might not have same impacts on the BMI of patients with schizophrenia.

No MeSH data available.


Related in: MedlinePlus